NCT03540043View on ClinicalTrials.gov

Thykamine Safety and Efficacy Study in Mild-to-Moderate Atopic Dermatitis

PHASE2CompletedINTERVENTIONAL
Enrollment

162

Participants

Timeline

Start Date

October 23, 2017

Primary Completion Date

December 31, 2019

Study Completion Date

June 3, 2020

Conditions
Atopic Dermatitis Eczema
Interventions
DRUG

Administration of Placebo

Botanical Drug Phase 2 clinical study

DRUG

Administration of PUR0110 (Thykamine) 0.05%

Botanical Drug Phase 2 clinical study

DRUG

Administration of PUR0110 (Thykamine) 0.1%

Botanical Drug Phase 2 clinical study

DRUG

Administration of PUR0110 (Thykamine) 0.25%

Botanical Drug Phase 2 clinical study

Trial Locations (12)

L4M 7G1

SimcoDerm Medical and Surgical Dermatology Center, Barrie

L7M 4Y1

Manna Research Inc. (Burlington North), Burlington

N6H 5L5

DermEffects, London

L3P 1X2

Lynderm Research inc., Markham

M9W 4L6

Manna Research Inc. (Toronto), Toronto

N8W5L7

Windsor Clinical Research Inc., Windsor

L5H 1G9

DermEdge Research imc., Mississauga

G7H 7Y8

Q&T Research Chicoutimi, Chicoutimi

J2B 5L4

Dr. Isabelle Delorme Inc., Drummondville

H3H 1V4

Dr. David Gratton Dermatologue Inc., Montreal

G1W 4R4

Centre de Recherche Saint-Louis, Québec

G1V 4X7

Centre de Recherche Dermatologique du Quebec metropolitain (CRDQ), Québec

All Listed Sponsors
lead

PurGenesis Technologies Inc.

INDUSTRY

NCT03540043 - Thykamine Safety and Efficacy Study in Mild-to-Moderate Atopic Dermatitis | Biotech Hunter | Biotech Hunter